Dr. Lippman is a distinguished professor of medicine, director of MS program in Precision Medicine, and past director of the NCI Comprehensive Moores Cancer Center, Chair of UC Cancer Consortium, Chugai Pharmaceutical Chair; associate vice chancellor for cancer research at UCSD; adjunct professor at the Salk Institute, Sanford-Burnham Medical Research Institute and MD Anderson Cancer Center.

Dr. Lippman is an NIH R01-funded physician-scientist. His research is focused on genomics, immune oncology and precision medicine, publishing over 300 high-impact research articles; and elected member of the prestigious Association of American Physicians (AAP). He has been recognized in major “Top Doctor” listing including U.S. News & World Report, and received numerous awards, including from the American Cancer Society (ACS), American Society of Clinical Oncology (ASCO), Stand up to Cancer (SU2C), and the American Association for Cancer Research (AACR). His highest impact research is the discovery and first report of the pivotal role of chromosome 9 somatic copy-number alterations in immune-response and immune-checkpoint therapy resistance (e.g., senior author, PNAS 2021); and the breakthrough deep-learning AI platform published in the 2024 Journal of Clinical Oncology (co-senior author) and co-inventor on the related patents. He was a member of the Board of Directors for the AACR, the Association of American Cancer Institutes, and the National Comprehensive Cancer Network, and has served as a standing member on the FDA Oncologic Drugs Advisory Committee (ODAC).

Before joining UCSD in 2012, Dr. Lippman was on faculty at MD Anderson Cancer Center for 24 years, including as a tenured professor, where he held three endowed positions, and was distinguished chair of two departments. He received his medical degree from The Johns Hopkins University School of Medicine, and is triple-board certified in internal medicine, hematology, and medical oncology.